Expertise in
5
conditions

Lars H. Lindner

Mexicali C.P. 21280, 
Mexicali, BCN, MX 
Expertise in
5
conditions
Mexicali C.P. 21280, 
Mexicali, BCN, MX 

Overview

Lars Lindner practices practicing medicine in Mexicali, Mexico.

Mr. Lindner is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Lung Metastases, Alveolar Soft Part Sarcoma, Myxoid Liposarcoma, and Orchiectomy.

He is actively involved in clinical research, co-authoring 157 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Mexicali C.P. 21280, Mexicali, BCN 21280, Mexico

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: GSK3901961, GSK3845097, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Randomized, Double Blind, Phase II Trial of Pazopanib Versus Placebo as Maintenance Therapy in Patients With Retroperitoneal and Visceral High-risk Soft Tissue Sarcomas Following Prior Neo- and/or Adjuvant Doxorubicin / Ifosfamide Chemotherapy With Regional Hyperthermia
A Randomized, Double Blind, Phase II Trial of Pazopanib Versus Placebo as Maintenance Therapy in Patients With Retroperitoneal and Visceral High-risk Soft Tissue Sarcomas Following Prior Neo- and/or Adjuvant Doxorubicin / Ifosfamide Chemotherapy With Regional Hyperthermia
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma
Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma
Enrollment Status: Terminated
Publish Date: March 22, 2022
Intervention Type: Drug
Study Phase: Phase 2
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial
Enrollment Status: Terminated
Publish Date: September 22, 2021
Intervention Type: Drug
Study Drug: Pazopanib
Study Phase: Phase 4
View 4 Less Clinical Trials

157 Total Publications

Prognostic Factors and Survival Outcomes in Resectable Thoracic Soft Tissue and Bone Sarcomas.
Prognostic Factors and Survival Outcomes in Resectable Thoracic Soft Tissue and Bone Sarcomas.
Journal: Cancers
Published: May 12, 2026

Frequently Asked Questions about Lars H. Lindner

Is Lars H. Lindner a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Lars H. Lindner is classified as an Elite expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lars H. Lindner participate in research or clinical trials?

Yes. Lars H. Lindner has published 157 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Lars H. Lindner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lindner's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile